← GLP-1 Cross-Sector Effects
Cycle on May 20, 2026
Ran 15m 51s · 11 findings · 13 searches · 17 fetches
No events yet. The agent's first move will appear here in a moment.
Listed threads
Agent
No open threads — I'll dive straight into research across the topic's dimensions. Let me run several searches in parallel to cover the key areas.
🔍 Search
Novo Nordisk Eli Lilly GLP-1 pipeline new drug approvals 2026
No results.
🔍 Search
GLP-1 insurance coverage pricing Medicare Medicaid 2026
No results.
🔍 Search
bariatric surgery impact GLP-1 drugs medical device companies 2026
No results.
🔍 Search
GLP-1 new applications research addiction Alzheimer's 2026
No results.
🔍 Search
GLP-1 consumer adoption trends prescriptions data 2025 2026
No results.
Agent
Now let me fetch the most promising articles for actual content:
📥 Fetch
https://dmbio.com/blog/how-strong-were-eli-lilly-q1-2026-earnings
📥 Fetch
https://247wallst.com/investing/2026/05/14/is-eli-lilly-going-to-1100/
📥 Fetch
https://www.nytimes.com/2026/05/15/business/glp-1-weight-loss-drugs-cost-medicare.html
📥 Fetch
https://www.jdsupra.com/legalnews/medicare-s-50-per-month-glp-1-bridge-7827046/
📥 Fetch
https://www.businesswire.com/news/home/20260519548459/en/ForePass-Replicates-Effects-of-the-Most-Powerful-and-Invasive-Bariatric-Surgery-While-Dramatically-Outperforming-Leading-GLP-1
📥 Fetch
https://www.medpagetoday.com/psychiatry
🔍 Search
Wegovy alcohol addiction trial heavy drinking results 2026
1 result — show all
- Can Blood Sugar Influence Alcohol Use? What A New Study Reveals ↗ — mindbodygreen.com
🔍 Search
Kailera Therapeutics IPO obesity drug April 2026
No results.
🔍 Search
Novo Nordisk CagriSema Q1 2026 earnings pipeline update
No results.
🔍 Search
retatrutide Eli Lilly triple agonist Phase 3 results 2026
No results.
🔍 Search
GLP-1 restaurant food industry impact consumer spending 2026
No results.
📥 Fetch
https://www.indexbox.io/blog/kailera-therapeutics-ipo-a-new-challenger-in-the-obesity-drug-market/ ↗
https://www.indexbox.io/blog/kailera-therapeutics-ipo-a-new-challenger-in-the-obesity-drug-market/
📥 Fetch
https://www.ad-hoc-news.de/boerse/news/ueberblick/novo-nordisk-dual-pipeline-advances-high-dose-wegovy-fat-loss-data-and/69349130
📥 Fetch
https://www.fool.com/investing/2026/05/17/could-eli-lillys-next-weightloss-drug-waylay-wegov/
📥 Fetch
https://www.businesswire.com/news/home/20260519548459/en/ForePass-Replicates-Effects-of-the-Most-Powerful-and-Invasive-Bariatric-Surgery-While-Dramatically-Outperforming-Leading-GLP-1
📥 Fetch
https://www.tovima.com/science/how-glp-1-drugs-are-reshaping-americas-restaurant-industry/
📥 Fetch
https://kffhealthnews.org/health-industry/trump-stock-trades-eli-lilly-glp-1-weight-loss-drugs-invest-ethics-disclosures/
📥 Fetch
https://medicalxpress.com/news/2026-05-favored-nation-prices-medicare-glp.html
📥 Fetch
https://www.ad-hoc-news.de/boerse/news/ueberblick/novo-nordisk-s-oral-glp-1-launch-beats-forecasts-yet-india-price-war/69355997
📥 Fetch
https://www.ad-hoc-news.de/boerse/news/ueberblick/novo-nordisk-presses-forward-with-oral-semaglutide-and-amycretin-as/69382238
📥 Fetch
https://www.fool.com/investing/2026/05/16/is-kailera-therapeutics-a-buy-after-its-sizzling/
📥 Fetch
https://sgbonline.com/exec-hoka-parent-and-nike-inc-downgraded-by-wells-fargo-on-glp-1-adoption-effect/
🔍 Search
Viking Therapeutics VK2735 Phase 3 GLP-1 2026 oral formulation
No results.
Agent
Good research across all dimensions. Let me now persist the key findings.
📝 Wrote finding
lilly-q1-2026-earnings-foundayo-launch
📝 Wrote finding
novo-nordisk-q1-2026-oral-wegovy-cagrisema
📝 Wrote finding
medicare-glp1-bridge-50-dollar-coverage
📝 Wrote finding
medicare-glp1-mfn-cost-neutrality-jama
📝 Wrote finding
trump-lilly-stock-purchases-govt-policy-tailwinds
Agent
Now let me continue with the remaining findings:
📝 Wrote finding
kailera-therapeutics-ipo-glp1-challenger
📝 Wrote finding
forepass-endoscopic-device-vs-glp1-bariatric-surgery
📝 Wrote finding
GLP-1 Drugs Reshaping Restaurant Industry: 12% of US Adults on Therapy, 8% Spending Cut at Fast Food
glp1-restaurant-industry-impact-consumer-spending
📝 Wrote finding
glp1-apparel-retail-impact-wells-fargo
Agent
I have a couple more angles to cover — the Wegovy addiction trial and a few secondary ripple effects — plus I should open some follow-up threads.
🔍 Search
"Wegovy" alcohol addiction trial results 2026 MedPage
No results.
🔍 Search
Supreme Court Medicare drug price negotiations GLP-1 2026
No results.
Agent
Let me open threads for the questions I couldn't fully resolve, and record a cycle summary.
🧵 Opened thread
open_questionWegovy alcohol addiction trial results — confirm findings and market size implications
🧵 Opened thread
open_questionSupreme Court Medicare price negotiation ruling — implications for GLP-1 pricing timeline
🧵 Opened thread
open_questionNIH study on GLP-1 hedonic eating suppression — implications for addiction and broader CNS applications
🧵 Opened thread
open_questionRetatrutide osteoarthritis and multi-indication data — quantify TAM expansion beyond obesity
🧵 Opened thread
QuestionWegovy alcohol addiction trial results — confirm findings and market size implications
🧵 Opened thread
QuestionSupreme Court Medicare price negotiation ruling — implications for GLP-1 pricing timeline
🧵 Opened thread
QuestionNIH study on GLP-1 hedonic eating suppression — implications for addiction and broader CNS applications
🧵 Opened thread
QuestionRetatrutide osteoarthritis and multi-indication data — quantify TAM expansion beyond obesity
Agent
Tracked 10 findings across Q1 earnings from both Lilly and Novo, the Medicare $50/month Bridge launching July 1, a JAMA study showing MFN pricing nearly achieves cost-neutrality, Trump's personal Lilly stock purchases during pro-GLP-1 policy actions, Kailera's $625M IPO as the first pure-play challenger, the ForePass endoscopic device outperforming semaglutide 8:1 preclinically, and measurable restaurant (8% spending cut) and apparel (40%+ higher clothing spend) ripple effects — plus four open questions on addiction trials, Supreme Court price negotiations, hedonic eating mechanisms, and retatrutide's multi-indication data.